1. Scrip
  2. >>COVID-19

COVID-19 Will Spur Decentralized and Hybrid Trials – Novartis Hails Digital Investment

Decentralized Trials Can Only Soften The Blow

 
• By Andrew McConaghie

The reality is that many trials requiring hospital based tests and interventions cannot be replaced, but crisis will spur take up where practical.

Novartis_Building
Novartis says its investment in digitizing clinical trial monitoring has helped during the crisis

For those looking for a silver lining to the COVID-19 pandemic in healthcare, the prospect of it spurring a move to more digitally enabled trials has become a frequently expressed hope. 

However in reality, while the pandemic is likely to increase uptake of ‘decentralised’ and ‘hybrid’clinical trial approaches in the long term, it won’t come close to

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

More from Scrip

Trump’s MFN Executive Order More Rhetoric Than Action

 
• By Jessica Merrill

The details of Trump’s latest executive order on drug pricing are vague and the president put more blame on other countries and pharma distributors than drug companies.

Biopharma Deals ROI Has Fallen And Market Instability Could Make It Worse

 
• By Andrew McConaghie

Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.

Executives On The Move: Altesa BioSciences Acquires Chief Medical Officer From GSK, Scholar Rock Gets A New CEO, And More

Recent moves in the industry include C-suite changes at Scholar Rock and Augustine Therapeutics, plus Contineum Therapeutics acquires chief medical officer from Gilead Sciences.